Literature DB >> 29066571

Individual testosterone decline and future mortality risk in men.

Stine A Holmboe1,2, Niels E Skakkebæk3,2, Anders Juul3,2,4, Thomas Scheike5, Tina K Jensen3,2, Allan Linneberg4,6,7, Betina H Thuesen6, Anna-Maria Andersson3,2.   

Abstract

OBJECTIVE: Male aging is characterized by a decline in testosterone (TS) levels with a substantial variability between subjects. However, it is unclear whether differences in age-related changes in TS are associated with general health. We investigated associations between mortality and intra-individual changes in serum levels of total TS, SHBG, free TS and LH during a ten-year period with up to 18 years of registry follow-up.
DESIGN: 1167 men aged 30-60 years participating in the Danish Monitoring Trends and Determinants of Cardiovascular Disease (MONICA1) study and who had a follow-up examination ten years later (MONICA10) were included. From MONICA10, the men were followed up to 18 years (mean: 15.2 years) based on the information from national mortality registries via their unique personal ID numbers.
METHODS: Cox proportional hazard models were used to investigate the association between intra-individual hormone changes and all-cause, CVD and cancer mortalities.
RESULTS: A total of 421 men (36.1%) died during the follow-up period. Men with most pronounced decline in total TS (<10th percentile) had a higher all-cause mortality risk compared to men within the 10th to 90th percentile (hazard ratio (HR): 1.60; 95% confidence interval (CI): 1.08-2.36). No consistent associations were seen in cause-specific mortality analyses.
CONCLUSION: Our study showed that higher mortality rates were seen among the men who had the most pronounced age-related decline in TS, independent of their baseline TS levels.
© 2018 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29066571     DOI: 10.1530/EJE-17-0280

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

Review 1.  Paediatric and adult-onset male hypogonadism.

Authors:  Andrea Salonia; Giulia Rastrelli; Geoffrey Hackett; Stephanie B Seminara; Ilpo T Huhtaniemi; Rodolfo A Rey; Wayne J G Hellstrom; Mark R Palmert; Giovanni Corona; Gert R Dohle; Mohit Khera; Yee-Ming Chan; Mario Maggi
Journal:  Nat Rev Dis Primers       Date:  2019-05-30       Impact factor: 52.329

2.  Endothelin B receptor dysfunction mediates elevated myogenic tone in cerebral arteries from aged male Fischer 344 rats.

Authors:  Alexander P Young; Jiequan Zhu; Amina M Bagher; Eileen M Denovan-Wright; Susan E Howlett; Melanie E M Kelly
Journal:  Geroscience       Date:  2021-01-05       Impact factor: 7.713

3.  Pre-treatment estradiol does not predict testosterone response to clomiphene citrate.

Authors:  John M Masterson; Jordan Cohen; Ruben Blachman-Braun; Graham L Machen; Jay Sandlow; Ranjith Ramasamy
Journal:  Transl Androl Urol       Date:  2020-04

4.  Exploring the usefulness of Lexis diagrams for quality improvement.

Authors:  Sara Dahlin
Journal:  BMC Med Inform Decis Mak       Date:  2020-01-08       Impact factor: 2.796

Review 5.  Anabolic-Androgenic Steroids and Exercise Training: Breaking the Myths and Dealing With Better Outcome in Sarcopenia.

Authors:  Hugo Falqueto; Marcelo Rodrigues Dos Santos; Leandro H Manfredi
Journal:  Front Physiol       Date:  2022-03-17       Impact factor: 4.566

Review 6.  Sex differences in vascular aging in response to testosterone.

Authors:  Kerrie L Moreau; Matthew C Babcock; Kerry L Hildreth
Journal:  Biol Sex Differ       Date:  2020-04-15       Impact factor: 5.027

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.